Findings from an on-treatment major bleeding analysis from the ENVISAGE TAVI AF trial, presented as a late-breaking trial at PCR London Valves (21–23 November, London, UK and virtual), underscore the importance of avoiding a combination of oral anticoagulants and antiplatelet drugs after transcatheter aortic valve implantation (TAVI) in patients with atrial fibrillation (AF) where it is avoidable.
This is according to Nicholas van Mieghem (Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands) who presented the findings at PCR London Valves. In conversation with Cardiovascular News, Van Mieghem provided an analysis of the findings from ENVISAGE TAVI AF, as well as discussing the recent release of five-year data from the SURTAVI trial, as well as offering his view on the future of research in TAVI.
